Loading...
•
Dec 31, 2021
Insmed Q4 2021 Earnings Report
Insmed reported financial results for Q4 2021, highlighting ARIKAYCE revenue and providing a business and pipeline update.
Key Takeaways
Insmed reported Q4 2021 total revenue of $56.1 million, compared to $41.4 million for Q4 2020. The company's cash position is expected to support ongoing programs into 2024.
ARIKAYCE total revenue was $56.1 million for Q4 2021 and $188.5 million for the full year 2021.
Insmed anticipates at least 30% year-over-year annual growth for 2022.
Enrollment timelines were provided for the Brensocatib Phase 3 ASPEN study and ARIKAYCE post-marketing studies (ARISE and ENCORE).
The company is planning to advance Brensocatib in two additional potential indications: Chronic Rhinosinusitis without Nasal Polyps (CRS) and Hidradenitis Suppurativa (HS).
Forward Guidance
Insmed expects full-year 2022 revenues for ARIKAYCE to increase at least 30% year over year from 2021 and anticipates that its cash on hand will support its ongoing programs into 2024.
Positive Outlook
- Commercialization and expansion of ARIKAYCE globally
- Launch activities for ARIKAYCE in initial European countries and in Japan
- Advancement of the frontline clinical trial program for ARIKAYCE (ARISE and ENCORE)
- Advancement of brensocatib, including the Phase 3 ASPEN study in patients with bronchiectasis
- Advancement of the Phase 2 clinical development programs of TPIP
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...